Determination of orally administered all-trans-retinoic acid in human plasma by high-performance liquid chromatography.
All-trans-retinoic acid (RA) is used successfully in the treatment of acute promyelocytic leukaemia (APL), although unexplained relapses occur in many of the patients. Pharmacokinetic studies may help in understanding the mechanism of resistance to RA and a simple and rapid procedure for its determination in biological samples may be advantageous. A high-performance liquid chromatographic procedure is described, involving one-step extraction of RA from plasma, isocratic elution from a reversed-phase column (LiChrosorb RP-18, 5-microns particle size) and UV detection at 340 nm. The calibration graph is linear over a wide range and the limit of detection is approximately 10 ng/ml, using 0.5 ml of human plasma. The method is selective for RA, accurate and robust and thus suitable for the routine analysis of plasma samples from patients undergoing RA therapy. Analysis of plasma in a patient on RA therapy (45 mg/m2 per day) confirmed that during continuous treatment with RA the drug plasma concentrations are markedly lower at the time of relapse than on the first day of treatment.
Guiso
G
G
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Rambaldi
A
A
Dimitrova
B
B
Biondi
A
A
Caccia
S
S
D000284:Administration, Oral; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007202:Indicators and Reagents; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000188:drug therapy; D011786:Quality Control; D013056:Spectrophotometry, Ultraviolet; D014212:Tretinoin / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics
D007202:Indicators and Reagents; D014212:Tretinoin